Monte Rosa Therapeutics (GLUE) Operating Income: 2023-2025
Historic Operating Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$33.0 million.
- Monte Rosa Therapeutics' Operating Income fell 24.31% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 106.60%. This contributed to the annual value of -$81.1 million for FY2024, which is 43.40% up from last year.
- Monte Rosa Therapeutics' Operating Income amounted to -$33.0 million in Q3 2025, which was down 112.00% from -$15.6 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Operating Income peaked at $44.0 million during Q1 2025, and registered a low of -$37.2 million during Q2 2023.
- Over the past 3 years, Monte Rosa Therapeutics' median Operating Income value was -$33.0 million (recorded in 2025), while the average stood at -$20.8 million.
- Over the last 5 years, Monte Rosa Therapeutics' Operating Income had its largest YoY gain of 226.01% in 2025, and its largest YoY loss of 24.31% in 2025.
- Monte Rosa Therapeutics' Operating Income (Quarterly) stood at -$34.9 million in 2023, then skyrocketed by 137.30% to $13.0 million in 2024, then fell by 24.31% to -$33.0 million in 2025.
- Its Operating Income stands at -$33.0 million for Q3 2025, versus -$15.6 million for Q2 2025 and $44.0 million for Q1 2025.